Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2026-03-25 00:00:00 ET · period of report 2026-03-23 · accession 0001104659-26-034308 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-25 | 2026-03-23 | LGND | Sabba Stephen L | Dir | S - Sale | $207.87 | -1,000 | 32.8K | -3% | -$207.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-23 | S | D | 1,000 | $207.87 | 32,793 | D | — | — | (F1) These securities, as represented in Column 5, include a grant of 1,209 restricted shares approved by the Board of Directors of the Company at the 2025 Meeting held 6 June 2025, which shares were previously reported on a Form 4 for this Reporting Person dated 10 June 2025, and are included on this Form 4 only to report that they will vest in full within six (6) months from the date hereof. (F2) The price, as represented in Column 4, represents an average price per share of the following transactions on 23 March 2026: 100 shares at $208.055000, 17 shares at $207.980000, and 883 shares at $207.850000. |